Travere Therapeutics
TVTX
211 hedge funds and large institutions have $1.49B invested in Travere Therapeutics in 2025 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 76 increasing their positions, 69 reducing their positions, and 46 closing their positions.
337% more call options, than puts
Call options by funds: $32.5M | Put options by funds: $7.43M
10% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 69
2.7% more ownership
Funds ownership: 110.55% → 113.24% (+2.7%)
3% less funds holding
Funds holding: 218 → 211 (-7)
13% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 46
16% less capital invested
Capital invested by funds: $1.77B → $1.49B (-$285M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$33.4M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$16.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.2M |
| 4 |
PA
Perceptive Advisors
New York
|
+$13.8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$49.6M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$46.6M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$16.8M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$12.1M |
| 5 |
D.E. Shaw & Co
New York
|
-$9.66M |
TVTX Hedge Fund Activity: Q2 2025 in Review
211 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2025, worth a combined $1.49B — down 16% from $1.77B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of TVTX and 40 opened new positions — a net loss of 6 holders — while 69 trimmed existing stakes and 76 added.
The largest buyer was Janus Henderson Group, adding an estimated $33.4M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $49.6M sold.
- 211 institutional investors held Travere Therapeutics (TVTX) as of Q2 2025, down from 218 in Q1 2025.
- Funds reported $1.49B of Travere Therapeutics stock for Q2 2025, down 16% quarter-over-quarter.
- 40 funds opened new Travere Therapeutics positions in Q2 2025 and 46 closed out, a net change of -6 holders.
- The largest Travere Therapeutics buyer in Q2 2025 was Janus Henderson Group, an estimated $33.4M added.
- The largest Travere Therapeutics seller in Q2 2025 was Driehaus Capital Management, an estimated $49.6M sold.
Based on aggregated 13F filings for Q2 2025.